RAFAEL HOLDINGS, INC. Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired
RAFAEL HOLDINGS, INC. (RFL) reported Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired of $4.00 million for the 9-month period ending 2026-04-30, per its 10-Q filed 2026-06-11.
Financial Statements › Notes › Goodwill and Other
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired · last filed 2026-06-11
- RAFAEL HOLDINGS, INC. research and development asset acquired other than through business combination, fair value acquired for the quarter ending 2026-04-30 was $0.00.
- RAFAEL HOLDINGS, INC. research and development asset acquired other than through business combination, fair value acquired for the quarter ending 2026-01-31 was $0.00.
- RAFAEL HOLDINGS, INC. research and development asset acquired other than through business combination, fair value acquired for the quarter ending 2025-10-31 was $4.00M, a 0.00% change year-over-year.
- RAFAEL HOLDINGS, INC. research and development asset acquired other than through business combination, fair value acquired for the quarter ending 2025-07-31 was $0.00.
- RAFAEL HOLDINGS, INC. research and development asset acquired other than through business combination, fair value acquired for fiscal 2025 was $4.00M, a 0.00% change from fiscal 2024.
- RAFAEL HOLDINGS, INC. research and development asset acquired other than through business combination, fair value acquired for fiscal 2024 was $4.00M.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired 3 month | Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired 6 month | Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired 9 month | Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired 12 month |
|---|---|---|---|---|
| 2026-04-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-06-11 | $0.00 derived: sum of 2 quarters · filed 2026-06-11 | $4.00M 10-Q · filed 2026-06-11 | $4.00M derived: sum of 4 quarters · filed 2026-06-11 |
| 2026-01-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-03-16 | $4.00M 10-Q · filed 2026-03-16 | $4.00M derived: sum of 3 quarters · filed 2026-03-16 | $4.00M derived: sum of 4 quarters · filed 2026-03-16 |
| 2025-10-31 | $4.00M 10-Q · filed 2025-12-12 | $4.00M derived: sum of 2 quarters · filed 2025-12-12 | $4.00M derived: sum of 3 quarters · filed 2025-12-12 | $4.00M derived: sum of 4 quarters · filed 2025-12-12 |
| 2025-07-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-29 | $0.00 derived: sum of 2 quarters · filed 2025-10-29 | $0.00 derived: sum of 3 quarters · filed 2025-10-29 | $4.00M 10-K · filed 2025-10-29 |
| 2025-04-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-06-11 | $0.00 derived: sum of 2 quarters · filed 2025-06-11 | $4.00M 10-Q · filed 2025-06-11 | $4.00M derived: sum of 4 quarters · filed 2025-06-11 |
| 2025-01-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-03-14 | $4.00M 10-Q · filed 2025-03-14 | $4.00M derived: sum of 3 quarters · filed 2025-03-14 | |
| 2024-10-31 | $4.00M 10-Q · filed 2024-12-11 | $4.00M derived: sum of 2 quarters · filed 2024-12-20 | ||
| 2024-07-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-12-20 | $4.00M 10-K/A · filed 2024-12-20 | ||
| 2024-04-30 | $4.00M 10-Q · filed 2024-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |